Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML.
Herrmann H, Sadovnik I, Eisenwort G, Rülicke T, Blatt K, Herndlhofer S, Willmann M, Stefanzl G, Baumgartner S, Greiner G, Schulenburg A, Mueller N, Rabitsch W, Bilban M, Hoermann G, Streubel B, Vallera DA, Sperr WR, Valent P. Herrmann H, et al. Among authors: willmann m. Blood Adv. 2020 Oct 27;4(20):5118-5132. doi: 10.1182/bloodadvances.2020001742. Blood Adv. 2020. PMID: 33085758 Free PMC article.
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P. Hadzijusufovic E, et al. Among authors: willmann m. Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):243-50. doi: 10.1016/j.vetimm.2009.05.007. Epub 2009 May 18. Vet Immunol Immunopathol. 2009. PMID: 19505729 Free PMC article.
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P. Peter B, et al. Among authors: willmann m. Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17. Haematologica. 2011. PMID: 21242189 Free PMC article.
The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
Herrmann H, Kneidinger M, Cerny-Reiterer S, Rülicke T, Willmann M, Gleixner KV, Blatt K, Hörmann G, Peter B, Samorapoompichit P, Pickl W, Bharate GY, Mayerhofer M, Sperr WR, Maeda H, Valent P. Herrmann H, et al. Among authors: willmann m. Curr Cancer Drug Targets. 2012 Jan;12(1):51-63. doi: 10.2174/156800912798888992. Curr Cancer Drug Targets. 2012. PMID: 22165967
The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P. Peter B, et al. Among authors: willmann m. J Leukoc Biol. 2014 Jan;95(1):95-104. doi: 10.1189/jlb.1112609. Epub 2013 Sep 19. J Leukoc Biol. 2014. PMID: 24052572
155 results